Please assess the completion status of the following clinical trial:

Trial Title: Hutterite Influenza Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Group A:~Inclusion Criteria:~* Hutterites other than the healthy children who will be immunized. Although this category as a whole will be used to assess indirect benefit of the vaccine in the main analysis, Hutterites at high risk for influenza complications within this category will be assessed in a separate analysis. These are defined as anyone in one or more of the following groups:~* individuals aged ≥ 65 years~* children 23 months of age or less~* anyone with ≥ 1 of the following conditions severe enough to require regular medical follow-up or hospital care:~  * chronic cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis, and asthma)~ * diabetes mellitus and other metabolic diseases~ * cancer~ * immunodeficiency~ * immunosuppression (due to underlying disease and/or therapy)~ * renal disease~ * anemia~ * hemoglobinopathy~ * any condition that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.~Exclusion Criteria:~* There are no exclusion criteria for this category of participants.~Group B:~Inclusion Criteria:~* Healthy children aged 36 months to 15 years who will be immunized as part of the intervention.~Exclusion Criteria:~* Anaphylactic reaction to a previous dose of influenza vaccine~* Anaphylactic reaction to hepatitis A vaccine~* Anaphylactic reaction to neomycin~* Known IgE-mediated hypersensitivity to eggs manifested as hives~* Swelling of the mouth and throat, difficulty in breathing, hypotension, or shock~* Guillain-Barré syndrome within eight weeks of a previous influenza vaccine.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Influenza (Type: EXPERIMENTAL): Inactivated Influenza vaccination
- Control (Type: PLACEBO_COMPARATOR): Hepatitis A vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).